Medicalgorithmics, a WSE-listed developer of an innovative platform and AI algorithms for ECG analysis, has signed an agreement with CardioDiagnostics, another major American IDTF specialising in heart monitoring and remote diagnostics through cloud-based software and certified devices for clinical ECG monitoring. Under the agreement, Medicalgorithmics’ innovative DeepRhythmAI (DRAI) AI algorithms will be integrated into the American partner’s software and will thus be available to current and future customers. The agreement has minimums and, in the opinion of the Management Board of Medicalgorithmics, has great potential and will contribute to a significant increase in the revenue growth of the Polish medtech company already in the first quarter of this year.
Following a record year for Medicalgorithmics in 2025, we are not slowing down and are continuing our dynamic growth, particularly in North America – a huge cardiology market with multi-billion dollar potential. Thanks to global recognition following publication in the prestigious Nature Medicine and the smooth and effective integration of our new clients, we are gaining the trust of further significant entities. The integration of our unique DRAI with the software of another major IDTF from the US has great potential for further growth of Medicalgorithmics and will allow us to further increase our already very satisfactory revenue growth dynamics, in particular recurring revenues from ECG tests performed using our innovative algorithms – comments Dr Kris Siemionow, CEO of Medicalgorithmics, on the signing of the agreement.
CardioDiagnostics is an American medtech company specialising in cardiac care solutions with a focus on heart monitoring and remote diagnostics through cloud-based software and clinical electrocardiographic monitoring devices. The company develops scalable, HIPAA-compliant cloud platforms and mobile applications for remote patient monitoring that integrate data from wearable biosensors and support physicians in making diagnostic decisions. The American IDTF’s offering includes both multifunctional, wireless heart rhythm monitoring devices and 24/7 monitoring services with clinical reports prepared by certified technicians. Importantly, CardioDiagnostics has been acquired by CardioOne, which strategically strengthens its position in the US market and increases its growth potential.
The agreement concluded with CardioDiagnostics is another contract signed by Medicalgorithmics with an American IDTF. In January last year, the Polish medtech company signed an agreement with one of the largest American IDTFs (in terms of sessions) for the provision of services and licensing of its leading DeepRhythmPlatform (DRP) software with DeepRhythmAI (DRAI) artificial intelligence algorithms for the analysis of ECG signals from the American partner’s devices.
The entire year 2025 was a record-breaking one for Medicalgorithmics. Listed on the Warsaw Stock Exchange, the medtech company grew rapidly, acquiring new customers and activating existing ones – it signed a record 20 contracts (more than in 2024: 14), which translated into a significant increase in its share price (+85% in 2025). New partnerships include: the aforementioned cooperation with one of the five largest American IDTFs (extended in September last year, thanks to which the daily number of tests performed by the IDTF immediately increased by 118%), an agreement with a European IDTF, an agreement with an American deep-tech company specialising in the integration of advanced materials, sensors and artificial intelligence, and three commercial agreements for VCAST – on the Turkish market, the strategic Scandinavian market and in Saudi Arabia.